Marylore Chenel, Ph.D.

Chief Research Officer

Portrait-of-Marylore-Chenel_Pharmetheus

Bio

  • Joined Pharmetheus in 2021, serving as Chief Research Officer, part of the executive leadership team, and leading the PBPK-QSP Business Development Platform
  • Expertise includes model-informed drug development, clinical pharmacology and regulatory advices in therapeutic areas such as oncology/immuno-oncology, immuno-inflammation, cardiology, and diabetes
  • Previously worked as Head of Global Pharmacometrics and Clinical Pharmacokinetics at Servier, France, where she led a team supporting the drug development portfolio from research to submission including lifecycle management, as Head and Deputy Head of Clinical Pharmacometrics and Clinical Pharmacokinetics, as a Pharmacometrician at Servier, France, and as Postdoctoral Fellow at the University of Manchester, UK
  • PharmD (2000) and M.Sc. in Pharmacokinetics (2000) from the University of Paris V, France, and Ph.D in Pharmacokinetics – PKPD modeling from the University of Poitiers, France
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Physiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case studyPhase 1 interim population PK/PD modeling and recommended phase 2 dose exploration for IMM-1-104: A novel concept oral deep cyclic inhibitor of MEKA quantitative systems pharmacology framework of immunogenicity to propose mitigation strategies after subcutaneous administrationOptimizing Formulations for Treatment of Cryptococcal Meningoencephalitis in Sub-Saharan HIV Patients: Insights from PBPK ModelingBioavailability of a novel sustained-release pellet formulation of 5-flucytosine in healthy-fed participants for use in patients with cryptococcal meningitisPhysiologically based pharmacokinetic modelling to support design of microarray patches delivering antiretroviral drugs to HIV positive children.Absorption, Bioavailability, and Immunogenicity after Subcutaneous Administration: Evaluation of a Subcutaneous Platform within the Open Systems Pharmacology frameworkPhysiologically-based pharmacokinetic (PBPK) modeling to predict disease effects on 5-flucytosine pharmacokinetics (PK) in the context of a switch from an immediate release (IR) to a sustained release (SR) formulation.Development of a PBPK model to predict monoclonal antibody pharmacokinetics and bioavailability following subcutaneous administrationBioavailability of three novel oral, sustained-release pellets, relative to an immediate-release tablet containing 500 mg flucytosine: A randomized, open-label, crossover study in healthy volunteersPredicting disease effect on the pharmacokinetics (PK) of sustained and immediate release formulations by applying physiologically based pharmacokinetic (PBPK) modelling